SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants

LOS ANGELES and NEW TAIPEI CITY, Taiwan: LOS ANGELES and NEW TAIPEI CITY, Taiwan, Jan. 6, 2022 /PRNewswire/ -- SyneuRx™ International, (Taipei Exchange, ticker ID TT6575, www.syneurx.com), a pioneering developer of novel CNS (Central Nervous System) and anti-viral pharmaceuticals, today announced that its investigational oral SARS-CoV-2 (COVID-19) anti-viral drug candidate...

Click to view original post